A new drug approval is providing hope for many people living with ovarian cancer.
Some women have what is known as “platinum-resistant” cancer, that means the disease is no longer responding to platinum-based chemotherapy, the most common chemo drug used … Read more
Updated dose expansion data of the phase I STRO-002-GM1 study have been presented today by Ana Oaknin, Principal Investigator of the Vall d’Hebron Institute of Oncology’s (VHIO) Gynecological Malignancies Group, on the ground at the 2023 Annual Meeting of the … Read more
by Anita T. Shaffer
Efforts to target the folate metabolism network have entered a new stage, with the approval of a novel therapy directed at folate receptor–α and the potential for additional agents aimed at that target in solid tumors.… Read more
